• Site Top
  • Investing in Japan
  • Latest Updates
  • 2017
  • Success Story: AEGERION PHARMACEUTICALS K.K., a pharmaceutical company that specializes in the development and commercialization of innovative therapies for rare diseases, released an oral drug for homozygous familial hypercholesterolemia (HoFH)
Latest Updates

Success Story: AEGERION PHARMACEUTICALS K.K., a pharmaceutical company that specializes in the development and commercialization of innovative therapies for rare diseases, released an oral drug for homozygous familial hypercholesterolemia (HoFH)

May 17, 2017

Logo of AEGERION PHARMACEUTICALS K.K.AEGERION PHARMACEUTICALS K.K.—a Japanese subsidiary of Aegerion Pharmaceuticals Inc., a U.S. pharmaceutical company that specializes in the development and commercialization of innovative therapies for rare diseases—released an oral drug in December 2016 that features a new mechanism of action for homozygous familial hypercholesterolemia (HoFH). This drug raises hopes of alleviating the burden on Japanese patients suffering from this rare disease.

For more information about other cases, please see the Success Stories.

Share on Facebook
Share on Twitter
Share on LinkedIn
  • Biz match for India-Japan HSR Industries (Photo by Kazumiki Miura Courtesy of JARTS)
  • Business Matching Database (TTPP)
  • Online Trade Fair Database (J-messe)
  • Abenomics is progressing!
  • JAPAN VIDEOS DISCOVER the SPIRIT of JAPAN
  • Sharing Cool Japan with the world